0
Original Article |

Dopaminergic Mechanisms of Reduced Basal Ganglia Responses to Hedonic Reward During Interferon Alfa Administration

Lucile Capuron, PhD; Giuseppe Pagnoni, PhD; Daniel F. Drake, PhD; Bobbi J. Woolwine, MSW; James R. Spivey, MD; Ronald J. Crowe, PhD; John R. Votaw, PhD; Mark M. Goodman, PhD; Andrew H. Miller, MD
Arch Gen Psychiatry. 2012;69(10):1044-1053. doi:10.1001/archgenpsychiatry.2011.2094.
Text Size: A A A
Published online

Context  Inflammatory cytokines or cytokine inducers can alter basal ganglia activity, including reducing responsiveness to rewarding stimuli that may be mediated by cytokine effects on dopamine function.

Objectives  To determine whether long-term administration of the inflammatory cytokine interferon alfa reduces the basal ganglia response to reward and whether such changes are associated with decreased presynaptic striatal dopamine function and altered behavior.

Design  Cross-sectional and longitudinal studies.

Setting  Outpatient research unit and neuroimaging facilities at Emory University, Atlanta, Georgia.

Patients  Medically stable adults with chronic hepatitis C virus (HCV) infection eligible for interferon alfa treatment.

Main Outcome Measures  Neural activity in the ventral striatum during a hedonic reward task as measured by functional magnetic resonance imaging, uptake and turnover of radiolabeled fluorodopa F 18 (18F-dopa) in caudate and putamen using positron emission tomography, and interferon alfa–induced depression, anhedonia, fatigue, and neurotoxicity.

Results  Patients with HCV receiving interferon alfa for 4 to 6 weeks (n = 14) exhibited significantly reduced bilateral activation of the ventral striatum in the win vs lose condition of a gambling task compared with patients with HCV awaiting interferon alfa treatment (n = 14). Reduced activation of the ventral striatum was, in turn, significantly correlated with anhedonia, depression, and fatigue. In a separate longitudinal study, patients with HCV treated with interferon alfa for 4 to 6 weeks (n = 12) exhibited significantly increased 18F-dopa uptake and decreased 18F-dopa turnover in caudate and putamen and in the same ventral striatal regions identified in the functional magnetic resonance imaging study. Baseline and percentage change in 18F-dopa uptake and turnover were correlated with behavioral alterations, including depression, fatigue, and neurotoxicity, during interferon alfa administration.

Conclusions  These data replicate and extend findings that inflammatory stimuli, including inflammatory cytokines, such as interferon alfa, alter basal ganglia activity and behavior in association with significant changes in presynaptic striatal dopamine function consistent with decreased dopamine synthesis or release.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Place holder to copy figure label and caption
Grahic Jump Location

Figure 1. Group differences in striatal responses to a hedonic reward task. Neural activation in the ventral striatum was assessed by blood oxygen level–dependent (BOLD) responses in the win-lose condition of a gambling task using functional magnetic resonance imaging. A, Right and left regions of interest (ROIs) (depicted here) reflect maximal activation in the groups combined, and the average percentage of BOLD signal change corresponding to the win-lose contrast across all ROI voxels (right, left, or bilateral) was used for group comparisons and correlations with behavioral end points. B, The interferon alfa treatment group (IFN) had significantly decreased activation in the right, left, and bilateral ventral striatal regions compared with the untreated control group (CTL) (P < .01 for all comparisons). The color bar ranges from t = 0 to t = 8, with a group activation threshold of P < .005 uncorrected and a cluster size k ≥ 19 voxels (P < .05 corrected).

Place holder to copy figure label and caption
Grahic Jump Location

Figure 2. Relationship between activation in the ventral striatum and reduced motivation. Neural activation in the ventral striatum was assessed by blood oxygen level–dependent (BOLD) responses in the win-lose condition of a gambling task using functional magnetic resonance imaging in patients with hepatitis C virus receiving interferon alfa for 4 to 6 weeks (white dots) and those awaiting interferon alfa treatment (black dots). Significant correlations were found between ventral striatal activation and reduced motivation as measured by the Multidimensional Fatigue Inventory (MFI) (P < .001 in all cases).

Place holder to copy figure label and caption
Grahic Jump Location

Figure 3. Mean fluorodopa F 18 (18F-dopa) uptake before and after interferon alfa therapy. Patients with chronic hepatitis C virus were administered 18F-dopa followed by positron emission tomography before and after 4 to 6 weeks of interferon alfa treatment. Mean images from the sample as a whole before and during interferon alfa administration indicate significantly higher uptake of 18F-dopa in caudate and putamen during interferon alfa treatment. The color bar represents the range of uptake values (Ki [1/min]) from 0 to 0.02.

Place holder to copy figure label and caption
Grahic Jump Location

Figure 4. Fluorodopa F 18 (18F-dopa) uptake and effective dopamine turnover before (black dots) and during (white dots) interferon alfa therapy. Patients with chronic hepatitis C virus were administered 18F-dopa followed by positron emission tomography before (visit 1) and after 4 to 6 weeks of interferon alfa treatment (visit 2). A, The 18F-dopa uptake (Ki [1/min]) was measured using the Patlak method (see the “Methods” section) in putamen and caudate. Significant increases in 18F-dopa uptake were found during interferon alfa administration compared with baseline (putamen: P < .005 for all; caudate: P < .05 for all) (Table 3), B, Effective dopamine turnover (EDT) was calculated by the method of Sossi et al36 (see the “Methods” section) in putamen and caudate. Significant decreases in EDT were found during interferon alfa administration compared with baseline (putamen: P < .005 for all; caudate: P < .05 for all) (Table 3).

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs